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The asymmetric synthesis of 1,3-oxathiolan-5-one derivatives through an enzyme-catalyzed, dynamic
covalent kinetic resolution strategy is presented. Dynamic hemithioacetal formation combined with
intramolecular, lipase-catalyzed lactonization resulted in good conversions with moderate to good en-
antiomeric excess (ee) for the ﬁnal products. The process was evaluated for different lipase preparations,
solvents, bases, and reaction temperatures, where lipase B from Candida antarctica (CAL-B) proved most
efﬁcient. The substrate scope was furthermore explored for a range of aldehyde structures, together with
the potential access to nucleoside analog inhibitor core structures.
 2014 The Authors. Published by Elsevier Ltd. All rights reserved.1. Introduction
Asymmetric synthesis of chiral core structures remains an im-
portant ﬁeld in organic chemistry, particularly for the production of
active pharmaceutical ingredients. One such interesting motif is
constituted by the 1,3-oxathiolane core. This structure type, to-
gether with the related 1,3-oxathiolan-5-ones, are attractive tar-
gets, not only for their existence in natural products and broad
biological activities, but also due to their importance as in-
termediates for a range of highly successful and useful pharma-
ceuticals. For example, they possess inhibitory activities toward
human type-II (non-pancreatic) secretory phospholipase A2
(PLA2);1 the oxathionyl-nucleosides emtricitabine (Coviracil) and
lamivudine (3TC) remain two of the most potent antiviral drugs as
nucleoside reverse transcriptase inhibitors (NRTIs) for the treat-
ment of diseases, such as human immunodeﬁciency virus (HIV) or
hepatitis B.2,3 Since the initial discovery of the antiviral activity of
this motif, the synthesis of enantiomerically pure 1,3-oxathiolan-5-
one derivatives has received signiﬁcant attention.4e6 To induce
a chiral element into the highly sensitive oxathiolane skeleton,
biocatalytic transformations have long been a method of choice
owing to its high degree of stereoselectivity, high efﬁciency, mildhe CC BY-NC-ND license
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. Published by Elsevier Ltd. All righreaction conditions, and advantageous environmental properties.
For example, classical kinetic resolution protocols were used in the
preparation of a lamivudine intermediate through hydrolysis of the
undesired enantiomer.7e11
Although classical kinetic resolution processes are often very
efﬁcient, the maximum theoretical yield is limited to 50% while
maintaining the highest possible enantiomeric excess (ee) of the
respective transformation. This inherent limitation of the kinetic
resolution concept can however be circumvented through the in-
troduction of dynamics in the system. Continuous racemization of
the starting material in conjunction with the resolution process,
results in dynamic kinetic resolution (DKR), where the maximum
theoretical yield can reach 100%without reducing the enantiomeric
purity.12e17 The value of DKR protocols in enzyme-catalyzed
asymmetric synthesis has been successfully illustrated by, for ex-
ample, transition metal-catalyzed racemization of the sub-
strates.18,19 Another approach involves dynamic covalent reactions,
where the racemic substrate is continuously reformed through the
reversible nature of participating chemical bonds (Scheme 1).16,20,21
Both these approaches can be efﬁciently coupled to enzyme ca-
talysis, leading to kinetic resolution of the optimal product. The
dynamic covalent process can furthermore be extended to the
resolution of complex systems.22e27
Recently, we reported the in situ formation of 1,3-oxathiolan-5-
one derivatives through lipase-catalyzed g-lactonization from
a complex dynamic hemithioacetal system.26 Due to the reversible
hemithioacetal transformation, the unselected structures werets reserved.
Scheme 1. Asymmetric synthesis of 1,3-oxathiolan-5-ones through dynamic covalent
kinetic resolution (DCKR).
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products after the enzymatic transformation were obtained with
both high chemo- and stereoselectivities in a one-pot process. This
protocol is particularly useful for enzyme classiﬁcation and sub-
strate identiﬁcation, but further exploration of the scope and syn-
thetic utility of this reaction is warranted. Herein we present an
optimized asymmetric synthesis of 1,3-oxathiolan-5-one through
dynamic covalent kinetic resolution, using hemithioacetal chem-
istry coupled with a lipase-catalyzed cyclization, as well as its fur-
ther usage for the construction of oxathiolane nucleoside skeletons.2. Results and discussion
The kinetic resolution function of the overall protocol was based
on enzyme-catalyzed transformation of transient, intermediate
hemithioacetals. Lipases, which belong to the hydrolase class of
enzymes, have in this context proven very efﬁcient and selective for
transesteriﬁcation of secondary alcohols in organic solvents, and
together with other advantages, such as commercial availability,
absence of cofactor requirements, and broad substrate scope, they
were chosen for the resolution process. However, lipases from
different sources may behave differently toward the same trans-
formation, and in order to optimize the reaction conditions,
screening of a range of lipases for the kinetically controlled lacto-
nization step was initially performed. The lipases from Pseudomo-
nas ﬂuorescens (PFL), Burkholderia (Pseudomonas) cepacia (PS, PS-CI,
and PS-IM), Candida antarctica (CAL-B), and Candida rugosa (CRL),
were thus probed for the cyclization using a model reaction in-
volving isobutyraldehyde (1a) and methyl 2-sulfanylacetate (2).
The results clearly demonstrated the lipase differentiation (Table
1), and outside of the fact that PS and CRL did not catalyze the re-
action under the tested conditions, the use of PS-IM, PS-CI, and PFL
led to slow reaction progress and very low enantiomeric excess of
the product. The activities are in this case likely challenged by the
double role of methyl 2-sulfanylacetate; serving both as substrate
precursor and acyl donor. On the other hand, CAL-B provided rea-
sonable conversion and good stereoselectivity, with anTable 1
Enzyme-catalyzed dynamic covalent kinetic resolution with different lipasesa
Entry Enzyme Conversionb (%) eec (%)
1 CAL-B 35 77
2 PS-IM 11 14
3 PS-CI 8 17
4 PS 0 d
5 CRL 0 d
6 PFL 13 20
a Reactions were carried out with 1a (0.1 mmol), 2 (1.2 equiv), Et3N (0.5 equiv),
4A MS (20 mg), and lipase preparation (50 mg; 5 mg for CAL-B) in toluene (0.6 mL)
at 25 C for 3 days.
b Determined by 1H NMR spectroscopy.
c The ees of 4a were determined by HPLC analysis using Daicel Chiralpak OJ
column, 99:1 Hex/iPrOH.enantiomeric ratio (E-value) of 12. Thus, CAL-B was chosen for
further studies of the reaction.
Lipase catalysis is highly solvent-dependent, and this aspect was
next addressed for the current system using the model reaction
between compounds 1a and 2. Four enzyme-compatible solvents
were thus tested: toluene, tert-butyl methyl ether (TBME), diethyl
ether, and tetrahydrofuran (THF). The cyclized product 4a was
detected in all of the four solvents, of which toluene, the reaction
media with lowest polarity, resulted in better enantiomeric excess
while the reaction rate was similar to the others. This can be partly
ascribed to its low miscibility with water, thus not interrupting the
bound water layer on the surface of lipase.
The temperature, another crucial parameter for both the equi-
librium distribution and the stereoselectivity of the enzymatic
transformation, was subsequently studied. The model reaction was
therefore performed at temperatures ranging from 40 C to25 C.
In consistency with previous results, the enantioselectivities were
improved at lower temperatures, a result that can be explained by
a more rigid enzyme structure at lower temperatures, resulting in
a better ﬁtting of the optimal enantiomer. The larger activation-
energy differences (DDGz) with decreased temperatures can also
contribute to the higher enantioselectivity.28,29 The best ees were
obtained at 25 C, at which point the reaction rate was still rea-
sonably high.
Reversible hemithioacetal formation has proven useful for efﬁ-
cient formation of dynamic systems in both aqueous and organic
media.26,30 In organic solution, base catalysis has been shown to
accelerate the reversibility of the reaction, and displace the equi-
librium of the system toward the hemithioacetals. Thus, the effect
of organic bases on the conversion and stereoselectivity was also
investigated in the current study. Besides triethylamine (Et3N),
which was used in the aforementioned dynamic system, other
bases, such as morpholine, 4-methylmorpholine (NMM), 4-
methylimidazole, and 4-dimethylaminopyridine (DMAP) were
tested (Table 2). Among these, the reactions with 4-
methylmorpholine resulted in the best enantiomeric excess, but
showed slightly lower conversion than using Et3N within the same
timeframe. Incidentally, 4-methylmorpholine was also the weakest
base with a pKa around 7.4. It was also found that increasing the
amount of base led to faster reactions, but at the cost of diminished
enantioselectivity. This can be explained by the facilitation of the
non-enzymatic background cyclization upon higher degree of base,
although also resulting in an increase in reversibility rates. In the
case of single reactions compared to complex dynamic systems,
smaller amounts of base were sufﬁcient for attaining high re-
versibility rates.Table 2
Enzyme-catalyzed dynamic covalent kinetic resolution with different basesa
Entry Base Base amount
(equiv)
Conversionb (%) eec (%)
1 Triethylamine 0.1 48 80
2 Morpholine 0.1 12 d
3 4-Methylmorpholine 0.1 39 95
4 4-Methylimidazole 0.1 37 80
5 4-Dimethylaminopyridine 0.1 43 86
6 4-Methylmorpholine 0.5 42 83
7 4-Methylmorpholine 1.0 46 83
a Reactions were carried out with 1a (0.1 mmol), 2 (1.2 equiv), base, 4 A MS
(20 mg), and CAL-B (5 mg) in toluene (0.6 mL) at 25 C for 4 days.
b Determined by 1H NMR spectroscopy.
c The ees of 4a were determined by HPLC analysis using Daicel Chiralpak OJ
column, 99:1 Hex/iPrOH.
Table 3
Dynamic covalent kinetic resolution of aldehydesa
Entry R group Product Conversionb (%) eec (%)
1 4a 73 81
2 4b 55 85
3 4c 79 90
4 4d 67 92
5 4e 75 71
6 4f 16 83
7 4g 93 71
a Reactions were carried out with 1aeg (0.1 mmol), 2 (1.2 equiv), NMM
(0.1 equiv), 4 A MS (300 mg), and CAL-B (5 mg) in toluene (0.6 mL) at 25 C for 4
days.
b Determined by 1H NMR spectroscopy.
c The ees of 4a were determined by HPLC analysis using Daicel Chiralpak OJ
column.
Scheme 2. Synthesis to nucleoside 6, an important intermediate for 3TC.
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carried out, including lipase loading, substrate concentration, and
water activity of the solution. However, it was generally found that
the enantioselectivity decreased at higher conversion. At this point
it was suspected that methanol, formed as a side product from the
cyclization step, could potentially affect the reaction. It is known
that short linear alcohols can deactivate lipases through in-
terference with the hydration layer of the enzyme.31e34 Therefore,
2 equiv ofmethanol were added to the DKR system at the beginning
of the reaction in order to test this effect. A dramatically decreased
conversion was indeed observed, supporting the hypothesis of the
inhibitory effects of methanol for CAL-B. For the purpose of re-
moving the methanol produced during the reaction, two different
methods were adopted for the system. The ﬁrst one involved ad-
dition of anhydrous calcium chloride salt (CaCl2) into the solution.
CaCl2 is not only capable of interacting with methanol to form
a stable crystalline complex, but also serves as a salt-hydrate pair in
the solution to control the water activity.35,36 After the addition of
CaCl2, the conversion increased from 51% to 73%, while the enan-
tiomeric excess remained at a high level of 88%. However, there
appeared to be a limitation of methanol binding ability and sta-
bility, as the result varied signiﬁcantly between different aldehydes
and also upon changes of reaction conditions. The other method for
methanol removal was the addition of a large excess of molecular
sieves (MS), which would be able to trap the produced methanol.
By addition of 300 mg 4 A MS per reaction, the reaction went
smoothly with a conversion of 73% over a reasonable timeframe,
along with a good enantiomeric excess of 81%. More importantly,
the methanol trapping effect of MS proved more robust than CaCl2
when applied to other substrates or in other conditions.
After having identiﬁed optimized conditions for the model re-
action, a range of other aldehydes (1beg) were further evaluated,
most of which (4beg) gave moderate to good ees with reasonable
conversions. For substrates with more branched aliphatic sub-
stituents, such as 3-methylbutanal (1b), 2-ethylbutanal (1c), and
cyclohexanecarbaldehyde (1d), the enantioselectivities were high,
while for the long chain aldehyde octanal (1e), much lower enan-
tiomeric excess was obtained. These differences are likely due to
how well the structures can be accommodated into the active site
of CAL-B. Large substituents without other binding potentials, such
as the heptyl group, may have difﬁculty to ﬁt into the active site of
CAL-B.37,38
When an aromatic aldehyde was applied to this system (entry 6,
Table 3), the reactionwas very slow even at the higher temperature
of 0 C, whereas the enantiomeric excess remained at more than
80%. An aldehyde with a protected a-oxygen was also tested (entry
7, Table 3), as this could in principle provide a direct route to in-
teresting chiral NRTI’s, such as lamivudine or emtricitabine. Sur-
prisingly, despite the bulky nature of the protecting group, very
clean reactions with a high conversion from starting material to the
O-protected 1,3-oxathiolan-5-one 4g were achieved, albeit with
slightly lower enantioselectivity. This may also be ascribed to the
non-optimal ﬁt with the CAL-B stereospeciﬁcity pocket.
In order to demonstrate that the oxathiolan-5-ones, synthesized
with the dynamic covalent kinetic resolution protocol, in principle
could be used for the construction of oxathiolane nucleosides, we
performed a brief synthesis starting from racemic compound 4g
(Scheme 2). The lactone functionality was ﬁrst reduced with dii-
sobutyl aluminum hydride to the corresponding lactol, which was
subsequently acetylated using standard conditions to obtain oxa-
thiolane product 5 in two steps.39 This intermediate could then be
transformed to the corresponding O-protected nucleoside under
Vorbr€uggen conditions,2,39 using pre-silylated N4-acetylcytosine in
a trimethylsilyl iodide-catalyzed N-glycosylation procedure. The
obtained nucleoside 6 could in principle be further functionalized
or deprotected to obtain the pharmaceutical product 3TC.403. Conclusions
In summary, a dynamic covalent kinetic resolution protocol
based on reversible hemithioacetal formation was successfully
applied to the synthesis of 1,3-oxathiolan-5-one derivatives. Using
lipase-catalyzed resolution, selective lactonization of the substrate
structures was achieved in a one-pot process. After a series of op-
timizations of the reaction conditions by use of wild-type CAL-B,
good yields and enantioselectivities for a range of substrates were
obtained. Furthermore, some of the synthesized 1,3-oxathiolan-5-
one derivatives showed potential for a simple access to the core
structure of active pharmaceutical nucleoside analogs.
4. Experimental section
4.1. General
Reagents were obtained from commercial suppliers and used as
received. Lipase PS ‘Amano’ IM (EC 3.1.1.3) was purchased from
Amano Enzyme Inc. All other lipases: lipases from Pseudomonas
ﬂuorescens (PFL), Burkholderia (Pseudomonas) cepacia (PS and PS-CI),
Candida antarctica (CAL-B), and Candida rugosa (CRL) were pur-
chased from SigmaeAldrich. 1H and 13C NMRdatawere recorded on
a Bruker Avance 400 (100) MHz and/or a Bruker Avance 500
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(ppm) with CDCl3 (1H NMR d 7.26, 13C NMR d 77.0) or DMSO-d6 (1H
NMR d2.50,13CNMR d39.5) as internal standard. J values are given in
Hertz (Hz). Analytical high performance liquid chromatography
(HPLC)with chiral stationaryphasewasperformedonanHP-Agilent
1110 Series controller and a UV detector, using a Daicel Chiralpak OJ
column (4.6250 mm, 10 mm). Solvents for HPLC use were of spec-
trometric grade. ATR-IR spectroscopy was performed on a Thermo
Scientiﬁc Nicolet iS10 spectrometer. High resolution mass spec-
troscopy was performed by the Instrument station of the National
Center for Genetic Engineering and Biotechnology (BIOTEC), Thai-
land, and at the Institute of Chemistry at University of Tartu, Estonia.
Thin layer chromatography (TLC) was performed on precoated Pol-
ygram SIL G/UV 254 silica plates (0.20 mm, MachereyeNagel), vi-
sualized with UV-detection. Flash column chromatography was
performed on silica gel 60, 0.040e0.063 mm (SDS).
4.2. General procedure for dynamic covalent kinetic
resolution
Aldehydes 1aeg (0.1 mmol each), methyl 2-sulfanylacetate
(0.12 mmol), 4-methylmorpholine (0.01 mmol), and dry toluene
(0.75 mL) were added into a 1.5 mL sealed-cap vial containing CAL-
B (5 mg) and CaCl2 (20mg) or 4Amolecular sieves (300 mg). CAL-B
was dried under vacuum for 2 days before use. The vial was kept at
25 C without stirring, and 1H NMR was used to monitor the re-
action progress. After 4 days, the reaction mixture was ﬁltered
through a cotton-stoppered pipette. Then, saturated NH4Cl was
added, and the resulting mixture was kept stirring at rt for 30 min.
CH2Cl2 was subsequently added, and the aqueous layer was
extracted three times (3 mL CH2Cl2 each). The combined organic
layer was dried over MgSO4 and removed in vacuo. The crude
products were puriﬁed using column chromatography (Hexane/
EtOAc¼20:1 or 15:1).
4.3. General procedure for the synthesis of racemic
compounds
Aldehydes 1aeg (3 mmol), methyl 2-sulfanylacetate (3.6 mmol),
and Et3N (0.3 mmol), were dissolved in toluene (1 mL), to which
CAL-B (5 mg), and 4 A molecular sieves (10 mg) were added. The
mixture was stirred at 60 C for 6 days, and 1H NMR was used to
monitor the reaction progress. After completion of the reaction,
CAL-B was removed by ﬁltration, and the solution was washed by
saturated NH4Cl, while stirring at rt for 30 min. The mixture was
extracted with CH2Cl2 (3 mL3), and the organic layer was dried
over MgSO4 and evaporated in vacuo. The crude products were ﬁ-
nally puriﬁed using column chromatography (Hexane/EtOAc¼20:1
or 15:1).
4.3.1. 2-Isopropyl-1,3-oxathiolan-5-one (4a).1 Conversion: 73%, en-
antiomeric excess (ee): 81%, determined by HPLC analysis (Daicel
Chiralpak OJ column, 99:1 Hex/iPrOH, 0.5 mL/min; tR 26.8 min; tR
30.7 min). 1H NMR (500 MHz, CDCl3, 25 C) d 1.01 (d, J¼6.7 Hz, 3H,
CH3), 1.06 (d, J¼6.7 Hz, 3H, CH3), 2.06e2.16 (m, 1H, CH), 3.58 (d,
J¼16.3 Hz, 1H, CH2), 3.68 (d, J¼16.3 Hz, 1H, CH2), 5.31 (d, J¼2.9 Hz,
1H, CH); 13C NMR (125 MHz, CDCl3, 25 C) d 17.2, 18.1, 31.7, 34.5,
87.7, 173.3.
4.3.2. 2-Isobutyl-1,3-oxathiolan-5-one (4b). Conversion: 55%, en-
antiomeric excess (ee): 85%, determined by HPLC analysis (Daicel
Chiralpak OJ column, 99:1 Hex/iPrOH, 0.5 mL/min; tR 27.7 min; tR
30.0 min). 1H NMR (500 MHz, CDCl3, 25 C) d 0.95 (d, J¼6.7 Hz, 3H,
CH3), 0.97 (d, J¼6.7 Hz, 3H, CH3),1.61e1.68 (m, H, CH),1.78e1.88 (m,
1H, CH2), 1.91e2.00 (m, 1H, CH2), 3.60 (d, J¼16.5 Hz, 1H, CH2), 3.69
(d, J¼16.5 Hz, 1H, CH2), 5.54 (t, J¼6.6 Hz, 1H, CH); 13C NMR(125 MHz, CDCl3, 25 C) d 22.4, 22.5, 25.4, 31.8, 45.6, 81.3, 172.9.
HRMS: found 161.0640, calcd for C7H13O2S [MþHþ] 161.0631.
4.3.3. 2-(Pentan-3-yl)-1,3-oxathiolan-5-one (4c).41 Conversion:
79%, enantiomeric excess (ee): 90%, determined by HPLC analysis
(Daicel Chiralpak OJ column, 99:1 Hex/iPrOH, 0.5 mL/min; tR
19.7 min; tR 22.5 min). 1H NMR (500 MHz, CDCl3, 25 C) d 0.92 (t,
J¼7.4 Hz, 6H, (CH3)2), 1.30e1.40 (m, 1H, CH), 1.46e1.56 (m, 3H,
(CH2)2), 1.66e1.74 (m, 1H, (CH2)2), 3.56 (d, J¼16.7 Hz, 1H, CH2), 3.66
(d, J¼16.7 Hz, 1H, CH2), 5.50 (d, J¼6.4 Hz, 1H, CH); 13C NMR
(125 MHz, CDCl3, 25 C) d 11.1, 21.5, 21.9, 31.8, 46.4, 85.6, 173.1.
HRMS: found 175.0787, calcd for C8H15O2S [MþHþ] 175.0787.
4.3.4. 2-Cyclohexyl-1,3-oxathiolan-5-one (4d).11 Conversion: 67%,
enantiomeric excess (ee): 92%, determined by HPLC analysis (Daicel
Chiralpak OJ column, 99:1 Hex/iPrOH, 0.5 mL/min; tR 28.0 min; tR
32.1 min). 1H NMR (500 MHz, CDCl3, 25 C) d 1.02e1.33 (m, 6H,
(CH2)3), 1.67e1.83 (m, 4H, (CH2)2), 1.96 (d, J¼12.5 Hz, 1H, CH), 3.57
(d, J¼16.8 Hz,1H, CH2), 3.66 (d, J¼16.8 Hz,1H, CH2), 5.29 (s, 1H, CH);
13C NMR (125 MHz, CDCl3, 25 C) d 25.6, 26.2, 27.7, 28.9, 31.5, 43.9,
87.0, 173.1.
4.3.5. 2-Heptyl-1,3-oxathiolan-5-one (4e).26 Conversion: 75%, en-
antiomeric excess (ee): 71%, determined by HPLC analysis (Daicel
Chiralpak OJ column, 99:1 Hex/iPrOH, 0.5 mL/min; tR 42.0 min; tR
48.5 min). 1H NMR (500 MHz, CDCl3, 25 C) d 0.88 (t, J¼6.8 Hz, 3H,
CH3), 1.20e1.37 (m, 10H, (CH2)5), 1.78e1.86 (m, 1H, CH2), 1.96e2.06
(m, 1H, CH2), 3.62 (d, J¼16.6 Hz, 1H, CH2), 3.67 (d, J¼16.6 Hz, 1H,
CH2), 5.48 (t, J¼6.7 Hz, 2H, CH2); 13C NMR (125 MHz, CDCl3, 25 C)
d 14.2, 22.7, 25.1, 29.1, 31.8, 36.8, 82.6, 173.0.
4.3.6. 2-(Pyridin-2-yl)-1,3-oxathiolan-5-one (4f).26 Conversion:
16%, enantiomeric excess (ee): 83%, determined by HPLC analysis
(Daicel Chiralpak OJ column, 80:20 Hex/iPrOH, 0.5 mL/min; tR
51.8 min; tR 59.2 min). 1H NMR (500 MHz, CDCl3, 25 C) d 3.79 (d,
J¼16.4 Hz, 1H, CH2), 3.87 (d, J¼16.4 Hz, 1H, CH2), 6.50 (s, 1H, CH),
7.27e7.32 (m, 1H, CH), 7.44 (d, J¼7.8 Hz, 1H, CH), 7.76 (t, J¼7.8 Hz,
1H, CH), 8.61 (d, J¼4.8 Hz,1H, CH); 13C NMR (125MHz, CDCl3, 25 C)
d 31.7, 81.4, 119.8, 124.1, 137.3, 149.9, 157.0, 173.0.
4 . 3 . 7 . 2 - ( B e n z y l o x ym e t h y l ) - 1 , 3 - o x a t h i o l a n - 5 - o n e
(4g).40 Conversion: 93%, enantiomeric excess (ee): 71%, determined
by HPLC analysis (Daicel Chiralpak OD-H column, 95:5 Hex/iPrOH,
0.5 mL/min; tR 74.3 min; tR 80.3 min). 1H NMR (500 MHz, CDCl3,
25 C) d 3.51 (d, J¼16.3 Hz, 1H, CH2), 3.66 (dd, J1¼4.3 Hz, J2¼10.9 Hz,
1H, CH2), 3.68 (d, J¼16.3 Hz, 1H, CH2), 3.72 (dd, J1¼4.3 Hz,
J2¼10.9 Hz, 1H, CH2), 4.55 (s, 2H, CH2), 5.52 (t, J¼3.9 Hz, 1H, CH),
7.21e7.31 (m, 5H, CH), 7.44 (d, J¼7.8 Hz,1H, CH), 7.76 (t, J¼7.8 Hz,1H,
CH), 8.61 (d, J¼4.8 Hz, 1H, CH); 13C NMR (125 MHz, CDCl3, 25 C)
d 31.1, 73.1, 73.8, 79.9, 127.7, 128.0, 128.6, 137.3, 172.9.
4.4. 5-Acetoxy-2-benzyloxymethyl-1,3-oxathiolane (5)40
To a solution of 2-benzyloxymethyl-1,3-oxathiolan-5-one
(384 mg, 1.67 mmol) in anhydrous toluene (16 mL) was added
a solution of diisobutyl aluminum hydride in hexanes (1 M, 2.5 mL,
2.50 mmol) dropwise over 30 min at 78 C. The mixture was
stirred for 80 min under N2 atmosphere, keeping the temperature
below 70 C at all times. The reaction was quenched by dropwise
addition of cold, anhydrous methanol (5 mL) over 20 min and the
reaction mixture was stirred for a further 15 min at 78 C fol-
lowed by 2 h at rt. Washing with saturated aqueous Rochelle salt
solution (12 mL), distilled H2O (212 mL), and brine (212 mL),
followed by drying with MgSO4, ﬁltering, and concentration in
vacuo yielded a crude oil that was used in the next step without
further puriﬁcation. The crude product mixture was dissolved in
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was cooled to 0 C and evacuated two times with N2. Et3N
(0.23 mL, 1.67 mmol) was added dropwise under vigorous stirring
and the solution was stirred for 10 min, after which acetic anhy-
dride (0.20 mL, 2.12 mmol) and DMAP (65 mg, 0.53 mmol, dis-
solved in 0.5 mL CH2Cl2) were added via syringe. The solution was
slowly warmed to rt and stirred under N2 for 14 h. Quenching by
slow addition of saturated aqueous NaHCO3 solution (12 mL) was
followed by extraction of the aqueous phase with CH2Cl2
(312 mL). The combined organic phases were dried over MgSO4,
ﬁltered, and concentrated. Puriﬁcation by column chromatography
(19:1 to 15:1 hexanes/EtOAc) yielded an inseparable mixture of the
product diastereomers as a slightly yellow, viscous oil (232 mg,
0.87 mmol, 52%). trans-5: Rf 0.24 (Hexanes/EtOAc 8:1); 1H NMR
(500 MHz, CDCl3) d 7.29e7.36 (m, 5H), 6.69 (d, 1H, J¼4.3 Hz), 5.53
(dd, 1H, J¼4.5, 5.6 Hz), 4.62 (s, 2H), 3.73 (dd, 1H, J¼5.9, 10.6 Hz),
3.66 (dd, 1H, J¼4.2, 10.6 Hz), 3.31 (dd, 1H, J¼4.3, 11.5 Hz), 3.11 (d,
1H, J¼11.5 Hz); 2.09 (s, 3H); cis-5: Rf 0.24 (Hexanes/EtOAc, 8:1); 1H
NMR (500 MHz, solvent) d 7.29e7.36 (m, 5H), 6.59 (d, 1H,
J¼4.1 Hz), 5.51 (dd, 1H, J¼2.3, 4.9 Hz), 4.61 (s, 2H), 3.78 (dd, 1H,
J¼7.0, 10.5 Hz), 3.73 (dd, 1H, J¼5.9, 10.6 Hz), 3.28 (dd, 1H, J¼4.2,
11.8 Hz), 3.15 (d, 1H, J¼11.8 Hz); 1.99 (s, 3H);13 C NMR (125 MHz,
CDCl3, mixture of diastereomers) d 169.8, 169.7, 137.8, 137.7, 128.5,
128.0, 127.82, 127.77, 127.75, 127.68, 99.3, 99.1, 86.1, 84.6, 74.2, 73.6,
73.4, 72.4, 38.0, 37.4, 21.2, 21.1.
4.5. 2-Benzyloxymethyl-1,3-oxathiolan-5-yl-N4-acetylcyto-
sine (6)
Silylated N4-acetylcytosine was generated in situ by stirring N-
acetylcytosine42 (55.4 mg, 0.362 mmol) with hexamethyldisilazane
(1.0 mL, 4.8 mmol) and a crystal of (NH4)2SO4 at reﬂux (135 C)
under argon until all solid had dissolved (approximately 3 h). The
solution was slowly cooled to rt, and the hexamethyldisilazane was
removed under anhydrous conditions. The system was evacuated
ﬁve times with argon, and dried under vacuum for 30 min.
Meanwhile, 5-acetoxy-2-benzyloxymethyl-1,3-oxathiolane
(60.0 mg, 0.224 mmol) was dissolved in anhydrous acetonitrile
(6 mL) and stirred with pre-activated 3 A molecular sieves for
30 min under N2. The solution was transferred via syringe to the
dried silylated N4-acetylcytosine, and the resulting solution was
cooled to 0 C. TMSI (70.0 mL, 0.504 mmol) was added dropwise
over 15 min and the resulting yellow solution was stirred under
argon at 0 C for 1 h. The reaction was quenched by addition of
a mixture of ethyl acetate (10 mL) and aqueous NaHCO3 solution
(5 wt %, 6 mL) and the resulting two-phase systemwas stirred at rt
for 15 min. The mixture was further diluted with ethyl acetate
(10 mL) and the organic phase was washed with saturated aqueous
NaHCO3 solution (15 mL), distilled H2O (215 mL), and brine
(215 mL). Drying with MgSO4, ﬁltration, and concentration in
vacuo yielded the crude product mixture as a yellow solid. Puriﬁ-
cation by column chromatography (EtOAc) allowed for separation
of the diastereoisomers to yield the trans (28.7 mg, 0.127 mmol,
35%) and cis (34.4mg, 0.157mmol, 43%) isomers as white solids. cis-
6: Rf 0.09 (EtOAc); 1H NMR (500 MHz, CDCl3) d 9.43 (s, br, 1H), 8.39
(d, 1H, J¼7.5 Hz), 7.35e7.41 (m, 5H), 7.23 (d, 1H, J¼7.5 Hz), 6.34 (dd,
1H, J¼2.3, 5.2 Hz), 5.36 (t, 1H, J¼3.2 Hz), 4.65 (s, 2H), 4.04 (dd, 1H,
J¼2.8, 11.2 Hz), 3.83 (dd, 1H, J¼3.6, 11.2 Hz), 3.58 (dd, 1H, J¼5.4,
12.7 Hz), 3.22 (dd, 1H, J¼2.2, 12.7 Hz), 2.25 (s, 3H); 13C NMR
(125 MHz, CDCl3) d 170.6, 162.9, 154.9, 145.6, 137.1, 128.6, 128.2,
127.7, 96.0, 87.5, 73.9, 69.5, 39.5, 29.7, 24.9; 1D-NOE NMR pulse at
6.34 ppm, d 8.39, 5.36, 3.58, 3.22; 1D-NOE NMR pulse at 5.36 ppm,
d 6.34, 4.04, 3.83, 3.58; trans-6: Rf 0.12 (EtOAc); 1H NMR (500 MHz,
CDCl3) d 9.15 (s, br, 1H), 7.74 (d, 1H, J¼7.5 Hz), 7.41 (d, 1H, J¼7.5 Hz),
7.28e7.36 (m, 5H), 7.47 (dd, 1H, J¼1.6, 5.1 Hz), 5.68 (t, 1H, J¼4.9 Hz),
4.60 (s, 2H), 3.61e3.65 (m, 3H), 3.21 (dd, 1H, J¼1.7, 12.5 Hz), 2.25 (s,3H); HRMS: found 362.1169, calcd for C17H20N3O4S [MþHþ]
362.1169.
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